Answers are grounded in this paper and cite their sources.
Retrospective review investigates outcomes of CPC in children with TP53 variant, indicating prognosis challenges.
Background Choroid plexus carcinoma (CPC) is a rare pediatric brain tumor frequently associated with germline TP53 mutations. In Brazil, the R337H founder variant is particularly prevalent and may influence disease behavior and outcomes. Methods A retrospective review was conducted including 21 patients with CPC, between 2004 – 2024, treated at a single center in Brazil. Results This study analyzed 21 patients with choroid plexus carcinoma (median age: 1.0 year; 57% male). Tumors were predominantly located in the right lateral ventricle (62%). At diagnosis, 71% of cases were localized and 29% metastatic. Complete surgical resection was achieved in 71% (n = 15). Li-Fraumeni Syndrome (LFS) was confirmed in 71% of the cohort (n = 15); the TP53 R337H variant was the most common 43% (n = 9), while other variants (H179R, R248W, R110C, R158H) were less frequent. Regarding treatment, only three patients received upfront high-dose chemotherapy with autologous stem cell transplantation (AuSCT), while 18 received conventional chemotherapy, primarily the CPT-SIOP-2000 protocol. No patient received radiation at first treatment. For the entire cohort, the 2-year and 5-year Event-Free Survival (EFS) were 45.8% and 12.0%, respectively, while Overall Survival (OS) was 89.7% and 67.6%. In a comparative analysis, R337H carriers (n = 9) exhibited a median OS of 134.3 months and EFS of 19.4 months. In contrast, patients with other TP53 variants (n = 4) achieved 100% 5-year OS and EFS. Although R337H carriers showed a trend toward inferior outcomes, this was not statistically significant (OS p = 0.091; EFS p = 0.352). Among LFS patients who did not undergo upfront AuSCT (n = 13), the 2-year EFS and OS were 50.8% and 91.7%, respectively. Second malignancies occurred in three patients (thymic carcinoma, osteosarcoma, and high-grade glioma). Conclusions The TP53 R337H mutation is a distinct driver of CPC in Brazil, showing a tendency for worse prognosis than other TP53 variants. Improving long-term EFS remains a critical challenge.
No takes yet. Share an insight, caveat, or question.
Rodrigues et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: